Clinical and virological significance of the co-existence of HBsAg and anti-HBs antibodies in hepatitis B chronic carriers

Virology

Volumn 367, Issue 1, 2007, Pages 30-40

  Colson, Philippe ^a,b   Borentain, Patrick ^c   Motte, Anne ^a,b   Henry, Mireille ^a,b   Moal, Valérie ^c   Botta Fridlund, Danielle ^c   Tamalet, Catherine ^a,b   Gérolami, René ^c  

^a TIMONE HOSPITAL   (France)

^b CNRS   (France)

^c HÔPITAL DE LA CONCEPTION   (France)

Author keywords

Concurrent HBsAg and anti HBs antibodies detection; HBV chronic infection; HBV mutants; HBV reverse transcriptase; Hepatitis B virus

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; TACROLIMUS; TENOFOVIR DISOPROXIL; VIRUS ANTIBODY;

ADULT; AGED; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEROLOGY; VIROLOGY; VIRUS CARRIER;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; CARRIER STATE; FEMALE; FRANCE; GENOTYPE; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIV-1 REVERSE TRANSCRIPTASE; HOSPITALS, PUBLIC; HUMANS; MALE; MIDDLE AGED; PREVALENCE;

HEPATITIS B VIRUS;

EID: 34548678899     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2007.05.012     Document Type: Article

References (35)

1. Carman W.F. The clinical significance of surface antigen variants of hepatitis B virus. J. Viral Hepatitis 4 Suppl. 1 (1997) 11-20
2. Carman W.F., Zanetti A.R., Karayiannis P., Waters J., Manzillo G., Tanzi E., Zuckerman A.J., and Thomas H.C. Vaccine-induced escape mutant of hepatitis B virus. Lancet 336 8711 (1990) 325-329
3. Cooreman M.P., Leroux-Roels G., and Paulij W.P. Vaccine- and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen. J. Biomed. Sci. 8 3 (2001) 237-247
4. Foutch P.G., Carey W.D., Tabor E., Cianflocco A.J., Nakamoto S., Smallwood L.A., and Gerety R.J. Concomitant hepatitis B surface antigen and antibody in thirteen patients. Ann. Intern. Med. 99 4 (1983) 460-463
5. Hayashi J., Noguchi A., Nakashima K., Morofuji M., and Kashiwagi S. Frequency of concurrence of hepatitis B surface antigen and antibody in a large number of carriers in Okinawa, Japan. Gastroenterol. Jpn. 25 5 (1990) 593-597
6. Heijtink R.A., van Hattum J., Schalm S.W., and Masurel N. Co-occurrence of HBsAg and anti-HBs: two consecutive infections or a sign of advanced chronic liver disease?. J. Med. Virol. 10 2 (1982) 83-90
7. Hsu H.Y., Chang M.H., Liaw S.H., Ni Y.H., and Chen H.L. Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan. Hepatology 30 5 (1999) 1312-1317
8. Kfoury Baz E.M., Zheng J., Mazuruk K., Van Le A., and Peterson D.L. Characterization of a novel hepatitis B virus mutant: demonstration of mutation-induced hepatitis B virus surface antigen group specific "a"; determinant conformation change and its application in diagnostic assays. Transfus. Med. 11 5 (2001) 355-362
9. Kohno H., Inoue T., Tsuda F., Okamoto H., and Akahane Y. Mutations in the envelope gene of hepatitis B virus variants co-occurring with antibody to surface antigen in sera from patients with chronic hepatitis B. J. Gen. Virol. 77 Pt. 8 (1996) 1825-1831
10. Konopnicki D., Mocroft A., de Wit S., Antunes F., Ledergerber B., Katlama C., Zilmer K., Vella S., Kirk O., and Lundgren J.D. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 19 6 (2005) 593-601
11. Kumar S., Tamura K., and Nei M. MEGA: molecular evolutionary genetics analysis software for microcomputers. Comput. Appl. Biosci. 10 2 (1994) 189-191
12. Lada O., Benhamou Y., Poynard T., and Thibault V. Coexistence of hepatitis B surface antigen (HBs Ag) and anti-HBs antibodies in chronic hepatitis B virus carriers: influence of "a" determinant variants. J. Virol. 80 6 (2006) 2968-2975
13. Lee K.M., Kim Y.S., Ko Y.Y., Yoo B.M., Lee K.J., Kim J.H., Hahm K.B., and Cho S.W. Emergence of vaccine-induced escape mutant of hepatitis B virus with multiple surface gene mutations in a Korean child. J. Korean Med. Sci. 16 3 (2001) 359-362
14. Lin X., Yuan Z.H., Wu L., Ding J.P., and Wen Y.M. A single amino acid in the reverse transcriptase domain of hepatitis B virus affects virus replication efficiency. J. Virol. 75 23 (2001) 11827-11833
15. Lu M., and Lorentz T. De novo infection in a renal transplant recipient caused by novel mutants of hepatitis B virus despite the presence of protective anti-hepatitis B surface antibody. J. Infect. Dis. 187 8 (2003) 1323-1326 (Electronic publication 2003 March 26)
16. Ly T.D., Servant-Delmas A., Bagot S., Gonzalo S., Ferey M.P., Ebel A., Dussaix E., Laperche S., and Roque-Afonso A.M. Sensitivities of four new commercial hepatitis B virus surface antigen (HBsAg) assays in detection of HBsAg mutant forms. J. Clin. Microbiol. 44 7 (2006) 2321-2326
17. Margeridon S., Lachaux A., Trepo C., Zoulim F., and Kay A. A quasi-monoclonal anti-HBs response can lead to immune escape of 'wild-type' hepatitis B virus. J. Gen. Virol. 86 Pt 6 (2005) 1687-1693
18. Pawlotsky J.M. The concept of hepatitis B virus mutant escape. J. Clin. Virol. 34 Suppl. 1 (2005) S125-S129
19. Poland G.A., and Jacobson R.M. Clinical practice: prevention of hepatitis B with the hepatitis B vaccine. N. Engl. J. Med. 351 27 (2004) 2832-2838
20. Protzer-Knolle U., Naumann U., Bartenschlager R., Berg T., Hopf U., Meyer zum Buschenfelde K.H., Neuhaus P., and Gerken G. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 27 1 (1998) 254-263
21. Sheldon J., Rodes B., Zoulim F., Bartholomeusz A., and Soriano V. Mutations affecting the replication capacity of the hepatitis B virus. J. Viral Hepat. 13 7 (2006) 427-434
22. Shiels M.T., Taswell H.F., Czaja A.J., Nelson C., and Swenke P. Frequency and significance of concurrent hepatitis B surface antigen and antibody in acute and chronic hepatitis B. Gastroenterology 93 4 (1987) 675-680
23. Torresi J., Earnest-Silveira L., Civitico G., Walters T.E., Lewin S.R., Fyfe J., Locarnini S.A., Manns M., Trautwein C., and Bock T.C. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. Virology 299 1 (2002) 88-99
24. Torresi J., Earnest-Silveira L., Deliyannis G., Edgtton K., Zhuang H., Locarnini S.A., Fyfe J., Sozzi T., and Jackson D.C. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 293 2 (2002) 305-313
25. Tsang T.K., Blei A.T., O'Reilly D.J., and Decker R. Clinical significance of concurrent hepatitis B surface antigen and antibody positivity. Dig. Dis. Sci. 31 6 (1986) 620-624
26. Wang Y.M., Ng W.C., Kang J.Y., Yap I., Seet B.L., Teo J., Smith R., and Guan R. Serological profiles of hepatitis B carrier patients in Singapore with special reference to the frequency and significance of concurrent presence of HBsAg and anti-HBs. Singapore Med. J. 37 2 (1996) 150-152
27. Wang Y.M., Ng W.C., and Lo S.K. Detection of pre-S/S gene mutants in chronic hepatitis B carriers with concurrent hepatitis B surface antibody and hepatitis B surface antigen. J. Gastroenterol. 34 5 (1999) 600-606
28. Weber B. Genetic variability of the S gene of hepatitis B virus: clinical and diagnostic impact. J. Clin. Virol. 32 2 (2005) 102-112
29. Weinberger K.M., Zoulek G., Bauer T., Bohm S., and Jilg W. A novel deletion mutant of hepatitis B virus surface antigen. J. Med. Virol. 58 2 (1999) 105-110
30. Weinberger K.M., Bauer T., Bohm S., and Jilg W. High genetic variability of the group-specific a-determinant of hepatitis B virus surface antigen (HBsAg) and the corresponding fragment of the viral polymerase in chronic virus carriers lacking detectable HBsAg in serum. J. Gen. Virol. 81 Pt 5 (2000) 1165-1174
31. WHO. Hepatitis B (2002), WHO, Geneva
32. Yamamoto K., Horikita M., Tsuda F., Itoh K., Akahane Y., Yotsumoto S., Okamoto H., Miyakawa Y., and Mayumi M. Naturally occurring escape mutants of hepatitis B virus with various mutations in the S gene in carriers seropositive for antibody to hepatitis B surface antigen. J. Virol. 68 4 (1994) 2671-2676
33. Yim H.J., Hussain M., Liu Y., Wong S.N., Fung S.K., and Lok A.S. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 44 3 (2006) 703-712
34. Zheng X., Weinberger K.M., Gehrke R., Isogawa M., Hilken G., Kemper T., Xu Y., Yang D., Jilg W., Roggendorf M., and Lu M. Mutant hepatitis B virus surface antigens (HBsAg) are immunogenic but may have a changed specificity. Virology 329 2 (2004) 454-464
35. Zuckerman J.N., and Zuckerman A.J. Mutations of the surface protein of hepatitis B virus. Antiviral Res. 60 2 (2003) 75-78